Skip to content

Clinical trials

Observational Parkinson Disease trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Parkinson Disease Phase: Observational Country / region: Italy Clear all

100 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20063
20091
20102
20112
20136
20145
20152
20161
20177
20186
20199
20204
202110
202210
202314
20244
202510
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed36
Recruiting29
Unknown status25
Active, not recruiting6
Enrolling by invitation2
Not yet recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Neuromed IRCCS12
Ospedale Generale Di Zona Moriggia-Pelascini8
Fondazione Don Carlo Gnocchi ETS7
IRCCS San Raffaele5
Istituto Auxologico Italiano5
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico4
Abbott Medical Devices3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS3
IRCCS San Camillo, Venezia, Italy3
Istituti Clinici Scientifici Maugeri SpA3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Parkinson Disease100
Multiple Sclerosis10
Alzheimer Disease8
Cognitive Dysfunction8
Movement Disorders7
Neurodegenerative Diseases7
Stroke7
Multiple System Atrophy6
Amyotrophic Lateral Sclerosis5
Parkinsonian Disorders5

Trials

Showing 1 to 25 of 100. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.